{"id":4651,"date":"2024-07-03T11:51:37","date_gmt":"2024-07-03T11:51:37","guid":{"rendered":"https:\/\/digitaltradecenter.com\/index.php\/2024\/07\/03\/melodiol-q2-revenue-and-updates\/"},"modified":"2024-07-03T11:51:37","modified_gmt":"2024-07-03T11:51:37","slug":"melodiol-q2-revenue-and-updates","status":"publish","type":"post","link":"https:\/\/digitaltradecenter.com\/index.php\/2024\/07\/03\/melodiol-q2-revenue-and-updates\/","title":{"rendered":"Melodiol Q2 Revenue and Updates"},"content":{"rendered":"<p><strong>Melodiol Global Health Limited<\/strong> (ASX:ME1) (\u2018Melodiol\u2019 or \u2018the Company\u2019) is pleased to advise that it has delivered another strong revenue quarter. During Q2 of 2024, Melodiol generated unaudited revenue of$4.8m, a 9% increase on Q1 2024 ($4.4m). H2 2024 unaudited revenues now total $9.2m, a 31% increase on H1 2023 ($7.0m). <\/p>\n<p><strong>Highlights:<\/strong><\/p>\n<ul class='ee-ul'>\n<li>Q2 2024 unaudited revenues total $4.8m, a 9% increase on Q1 2024 ($4.4m)<\/li>\n<li>Brings H1 2024 unaudited revenues to $9.2m, a 31% increase on H1 2023 ($7.0m)<\/li>\n<li>Growth underpinned by strong results at Mernova <\/li>\n<\/ul>\n<div><\/div>\n<p>Growth was underpinned by strong results at Mernova. During Q2 of 2024, Mernova had confirmed unaudited purchase orders of $2.0m (C$1.8m). This figure is a 25% increase on Q1 2024 ($1.6m) and a 33% increase on Q2 2023 ($1.5m). In addition to these strong results, Mernova already has confirmed purchase orders for Q3 2024 of $452k (C$411k), providing a strong foundation for the quarter.<\/p>\n<p>Additionally, Mernova achieved a variety of key objectives, including the introduction of a new product category (edibles), the approval of numerous new SKUs in existing provinces, the introduction of new vaporiser flavours and a supply agreement to source additional capacity to keep up with strong demand.<\/p>\n<\/p>\n<p>In addition to these strong results, Mernova already has confirmed purchase orders for Q3 2024 of $452k (C$411k), providing a strong foundation for the quarter.<\/p>\n<p>During Q2 of 2024, HHI also provided $2.8m in sales between its Australian and UK divisions. As stated previously, the Company is committed to rationalising non-core business units, while focusing on its core divisions, Mernova and HHI in an effort to achieve profitability as quickly as possible.<\/p>\n<p><strong>Management commentary:<\/strong><\/p>\n<p><strong>CEO and Managing Director, Mr William Lay said<\/strong><strong>:<\/strong><em>\u201cWe are very pleased to demonstrate quarter on quarter growth for Melodiol as a group. During the last year, the Company has completed a step change in terms of revenue size, and we are sharply focused on Mernova and HHI as our core business units. By focusing on these business units, and rationalising non-core business units, all of our teams are working hard to achieve group profitability as quickly as possible.\u201d <\/em><em><\/em><\/p>\n<\/p>\n<p><strong>Click here for the full ASX Release<a href='https:\/\/cdn-api.markitdigital.com\/apiman-gateway\/ASX\/asx-research\/1.0\/file\/2924-02823957-6A1214269' target='_blank' rel=\"noopener\"><\/a><\/strong><\/p>\n<\/p>\n<div>This post appeared first on investingnews.com<\/div>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Melodiol Global Health Limited (ASX:ME1) (\u2018Melodiol\u2019 or \u2018the Company\u2019) is pleased to advise that it has delivered another strong revenue quarter. During Q2 of 2024, Melodiol generated unaudited revenue of$4.8m, a 9% increase on Q1 2024 ($4.4m). H2 2024 unaudited revenues now total $9.2m, a 31% increase on H1 2023 ($7.0m). Highlights: Q2 2024 unaudited <\/p>\n","protected":false},"author":1,"featured_media":4652,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":{"0":"post-4651","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/posts\/4651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/comments?post=4651"}],"version-history":[{"count":0,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/posts\/4651\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/media\/4652"}],"wp:attachment":[{"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/media?parent=4651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/categories?post=4651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/tags?post=4651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}